Patent ID: 11940448
Assignee: SEATTLE CHILDREN'S HOSPITAL
Field: Measurement (Instruments)
Classification: CPC G | IPC G

Claim 18:
19. An assay kit for the screening of Mucopolysaccharidosis Type I (MPSI) and/or Pompe Disease in a subject, the assay kit comprising:
(A) an antibody or antigen-binding fragment thereof comprising: a VH domain comprising a complementarity determining region (CDR)H1 as set forth in SEQ ID NO: 22, a CDRH2 as set forth in SEQ ID NO: 23, and a CDRH3 as set forth in SEQ ID NO: 24, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 25, a CDRL2 as set forth in SEQ ID NO: 26, and a CDRL3 as set forth in SEQ ID NO: 27; and
an antibody or antigen binding fragment thereof comprising: a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 66, a CDRH2 as set forth in SEQ ID NO: 67, and a CDRH3 as set forth in SEQ ID NO: 68, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 69, a CDRL2 as set forth in SEQ ID NO: 70, and a CDRL3 as set forth in SEQ ID NO: 71; or
(B) an antibody or antigen-binding fragment thereof comprising: a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 10, a CDRH2 as set forth in SEQ ID NO: 11, and a CDRH3 as set forth in SEQ ID NO: 12, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 13, a CDRL2 as set forth in SEQ ID NO: 14, and a CDRL3 as set forth in SEQ ID NO: 15; and
an antibody or antigen-binding fragment thereof comprising: a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 22, a CDRH2 as set forth in SEQ ID NO: 23, and a CDRH3 as set forth in SEQ ID NO: 24, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 25, a CDRL2 as set forth in SEQ ID NO: 26, and a CDRL3 as set forth in SEQ ID NO: 27; or
(C) an antibody or antigen-binding fragment thereof comprising: a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 10, a CDRH2 as set forth in SEQ ID NO: 11, and a CDRH3 as set forth in SEQ ID NO: 12, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 13, a CDRL2 as set forth in SEQ ID NO: 14, and a CDRL3 as set forth in SEQ ID NO: 15;
an antibody or antigen-binding fragment thereof comprising: a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 22, a CDRH2 as set forth in SEQ ID NO: 23, and a CDRH3 as set forth in SEQ ID NO: 24, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 25, a CDRL2 as set forth in SEQ ID NO: 26, and a CDRL3 as set forth in SEQ ID NO: 27; and
an antibody or antigen binding fragment thereof comprising: a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 66, a CDRH2 as set forth in SEQ ID NO: 67, and a CDRH3 as set forth in SEQ ID NO: 68, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 69, a CDRL2 as set forth in SEQ ID NO: 70, and a CDRL3 as set forth in SEQ ID NO: 71; or
(D) an antibody or antigen-binding fragment thereof comprising: a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 10, a CDRH2 as set forth in SEQ ID NO: 11, and a CDRH3 as set forth in SEQ ID NO: 12, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 13, a CDRL2 as set forth in SEQ ID NO: 14, and a CDRL3 as set forth in SEQ ID NO: 15;
an antibody or antigen-binding fragment thereof comprising: a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 22, a CDRH2 as set forth in SEQ ID NO: 23, and a CDRH3 as set forth in SEQ ID NO: 24, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 25, a CDRL2 as set forth in SEQ ID NO: 26, and a CDRL3 as set forth in SEQ ID NO: 27;
and an antibody or antigen binding fragment thereof comprising: a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 44, a CDRH2 as set forth in SEQ ID NO: 45, and a CDRH3 as set forth in SEQ ID NO: 46, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 47, a CDRL2 as set forth in SEQ ID NO: 48, and a CDRL3 as set forth in SEQ ID NO: 49; or
(E) an antibody or antigen binding fragment thereof comprising: a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 44, a CDRH2 as set forth in SEQ ID NO: 45, and a CDRH3 as set forth in SEQ ID NO: 46, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 47, a CDRL2 as set forth in SEQ ID NO: 48, and a CDRL3 as set forth in SEQ ID NO: 49; and
an antibody or antigen binding fragment thereof comprising: a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 66, a CDRH2 as set forth in SEQ ID NO: 67, and a CDRH3 as set forth in SEQ ID NO: 68, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 69, a CDRL2 as set forth in SEQ ID NO: 70, and a CDRL3 as set forth in SEQ ID NO: 71; or
(F) an antibody or antigen-binding fragment thereof comprising: a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 10, a CDRH2 as set forth in SEQ ID NO: 11, and a CDRH3 as set forth in SEQ ID NO: 12, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 13, a CDRL2 as set forth in SEQ ID NO: 14, and a CDRL3 as set forth in SEQ ID NO: 15;
an antibody or antigen-binding fragment thereof comprising: VH domain comprising a CDRH1 as set forth in SEQ ID NO: 22, a CDRH2 as set forth in SEQ ID NO: 23, and a CDRH3 as set forth in SEQ ID NO: 24, and VL domain comprising a CDRL1 as set forth in SEQ ID NO: 25, a CDRL2 as set forth in SEQ ID NO: 26, and a CDRL3 as set forth in SEQ ID NO: 27;
an antibody or antigen binding fragment thereof comprising: VH domain comprising a CDRH1 as set forth in SEQ ID NO: 44, a CDRH2 as set forth in SEQ ID NO: 45, and a CDRH3 as set forth in SEQ ID NO: 46, and VL domain comprising a CDRL1 as set forth in SEQ ID NO: 47, a CDRL2 as set forth in SEQ ID NO: 48, and a CDRL3 as set forth in SEQ ID NO: 49; and
an antibody or antigen binding fragment thereof comprising: a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 66, a CDRH2 as set forth in SEQ ID NO: 67, and a CDRH3 as set forth in SEQ ID NO: 68, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 69, a CDRL2 as set forth in SEQ ID NO: 70, and a CDRL3 as set forth in SEQ ID NO: 71; or
(G) an antibody or antigen-binding fragment thereof comprising: a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 10, a CDRH2 as set forth in SEQ ID NO: 11, and a CDRH3 as set forth in SEQ ID NO: 12, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 13, a CDRL2 as set forth in SEQ ID NO: 14, and a CDRL3 as set forth in SEQ ID NO: 15;
an antibody or antigen-binding fragment thereof comprising: a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 22, a CDRH2 as set forth in SEQ ID NO: 23, and a CDRH3 as set forth in SEQ ID NO: 24, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 25, a CDRL2 as set forth in SEQ ID NO: 26, and a CDRL3 as set forth in SEQ ID NO: 27;
an antibody or antigen binding fragment thereof comprising: a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 44, a CDRH2 as set forth in SEQ ID NO: 45, and a CDRH3 as set forth in SEQ ID NO: 46, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 47, a CDRL2 as set forth in SEQ ID NO: 48, and a CDRL3 as set forth in SEQ ID NO: 49; and
an antibody or antigen binding fragment thereof comprising: a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 66, a CDRH2 as set forth in SEQ ID NO: 67, and a CDRH3 as set forth in SEQ ID NO: 68, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 69, a CDRL2 as set forth in SEQ ID NO: 70, and a CDRL3 as set forth in SEQ ID NO: 71.